Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.
Phase 4
Not yet recruiting
- Conditions
- Hepatitis A
- Interventions
- Biological: Hepatitis A Vaccine
- Registration Number
- NCT06184230
- Lead Sponsor
- Best Healthcare Inc.
- Brief Summary
The goal of this clinical trial is to evaluate the persistence of Hepatitis A antibody \~32 years post vaccination in healthy adults. The questions this study will answer are: 1) how long antibody persists and 2) The immune response to an additional dose of vaccine among those with no detectable antibody. Participants will be asked to provide a blood specimen.
Those with no detectable antibody will be offered an additional dose of vaccine.
The kinetics of antibody response in this population will be summarized.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Consent obtained
- Participated in original hepatitis A study in 1991
- No detectable hepatitis A antibody ~32 years after study start
Exclusion Criteria
- Receipt of any dose of hepatitis A vaccine other than the hepatitis A vaccine used in the initial studies
- History of hepatitis A
- Receipt of blood transfusion or blood products, including immunoglobulins, within the past 6 months.
- Receipt of any vaccine within the 14 days before receipt of the additional dose of hepatitis A vaccine or scheduled to receive any vaccine within 30 days after receipt of a booster dose of vaccine.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Revaccinated at 32 Years Hepatitis A Vaccine -
- Primary Outcome Measures
Name Time Method Persistence of Antibody 32 Years Hepatitis A antibody
- Secondary Outcome Measures
Name Time Method